Unknown

Dataset Information

0

Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.

ABSTRACT: HIV-1-specific broadly neutralizing antibodies (bNAbs) can protect rhesus monkeys against simian-human immunodeficiency virus (SHIV) challenge. However, the site of antibody interception of virus and the mechanism of antibody-mediated protection remain unclear. We administered a fully protective dose of the bNAb PGT121 to rhesus monkeys and challenged them intravaginally with SHIV-SF162P3. In PGT121-treated animals, we detected low levels of viral RNA and viral DNA in distal tissues for seven days following challenge. Viral RNA-positive tissues showed transcriptomic changes indicative of innate immune activation, and cells from these tissues initiated infection after adoptive transfer into naïve hosts. These data demonstrate that bNAb-mediated protection against a mucosal virus challenge can involve clearance of infectious virus in distal tissues.

SUBMITTER: Liu J 

PROVIDER: S-EPMC5237379 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

HIV-1-specific broadly neutralizing antibodies (bNAbs) can protect rhesus monkeys against simian-human immunodeficiency virus (SHIV) challenge. However, the site of antibody interception of virus and the mechanism of antibody-mediated protection remain unclear. We administered a fully protective dose of the bNAb PGT121 to rhesus monkeys and challenged them intravaginally with SHIV-SF162P3. In PGT121-treated animals, we detected low levels of viral RNA and viral DNA in distal tissues for seven da  ...[more]

Similar Datasets

Transcriptomics Neutralizing Antibody Mediated Protection Against Mucosal Simian-Human Immunodeficiency Virus Challenge Includes Systemic Clearance of Distal Virus
2016-09-01 | GSE83702 | GEO
Unknown Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.
| S-EPMC5747528 | biostudies-literature
Unknown Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.
| S-EPMC4334439 | biostudies-literature
Unknown A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge.
| S-EPMC6755677 | biostudies-literature
Unknown Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
| S-EPMC3131343 | biostudies-literature
Unknown Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
| S-EPMC2674935 | biostudies-literature
Unknown Antibody-mediated protection against Ebola virus.
| S-EPMC6814399 | biostudies-literature
Unknown Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.
| S-EPMC6335502 | biostudies-other
Unknown Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge.
| S-EPMC7505435 | biostudies-literature
Unknown Novel malaria antigen Plasmodium yoelii E140 induces antibody-mediated sterile protection in mice against malaria challenge.
| S-EPMC7224506 | biostudies-literature